Cargando…

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis

OBJECTIVE: To establish the non-inferior efficacy of vonoprazan versus lansoprazole in the treatment of Asian patients with erosive oesophagitis (EO). DESIGN: In this phase III, double-blind, multicentre study, patients with endoscopically confirmed EO were randomised 1:1 to receive vonoprazan 20 mg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Yinglian, Zhang, Shutian, Dai, Ning, Fei, Guijun, Goh, Khean-Lee, Chun, Hoon Jai, Sheu, Bor-Shyang, Chong, Chui Fung, Funao, Nobuo, Zhou, Wen, Chen, Minhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Oesophagus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984055/ https://www.ncbi.nlm.nih.gov/pubmed/31409606 http://dx.doi.org/10.1136/gutjnl-2019-318365

Ejemplares similares

Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis
por: Vicario, M, et al.
Publicado: (2010)

IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis
por: Kaymak, Tanay, et al.
Publicado: (2023)

The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis
por: Furuta, Glenn T, et al.
Publicado: (2013)

The role of vonoprazan in patients with erosive esophagitis
por: Zhang, Mengyu, et al.
Publicado: (2022)

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
por: Turkington, Richard C, et al.
Publicado: (2019)

Reflux symptoms and oesophageal acidification in treated achalasia patients are often not reflux related
por: Ponds, Fraukje A, et al.
Publicado: (2021)

Computational modelling suggests that Barrett’s oesophagus may be the precursor of all oesophageal adenocarcinomas
por: Curtius, Kit, et al.
Publicado: (2021)

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer
por: Chong, Irene Yushing, et al.
Publicado: (2018)

Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas
por: Lin, De-Chen, et al.
Publicado: (2018)

The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis
por: Fisher, Oliver M, et al.
Publicado: (2017)

Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett's oesophagus
por: Lavery, Danielle L, et al.
Publicado: (2016)

Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease
por: Savarino, E, et al.
Publicado: (2009)

Post-transplant lymphoproliferative disorder as a cause of oesophageal ulceration and stricture: case report and literature review
por: Mukhtar, Mariam S, et al.
Publicado: (2021)

A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis
por: Miehlke, Stephan, et al.
Publicado: (2016)

Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma
por: Zhou, Jin, et al.
Publicado: (2022)

LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma
por: Li, Jiagen, et al.
Publicado: (2014)

Collagen type III alpha I is a gastro-oesophageal reflux disease susceptibility gene and a male risk factor for hiatus hernia
por: Åsling, B, et al.
Publicado: (2009)

A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
por: Keywood, C, et al.
Publicado: (2009)

Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett’s oesophagus and provides insights into clinical heterogeneity in reflux diagnosis
por: Ong, Jue-Sheng, et al.
Publicado: (2022)

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
por: Ashida, Kiyoshi, et al.
Publicado: (2018)

Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Circulating microRNAs as potential biomarkers to detect transformation of Barrett’s oesophagus to oesophageal adenocarcinoma
por: Matsuzaki, Juntaro, et al.
Publicado: (2017)

Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett’s oesophagus
por: Leedham, S J, et al.
Publicado: (2008)

Predictors for outcome of failure of balloon dilatation in patients with achalasia
por: Alderliesten, J, et al.
Publicado: (2010)

Use of proton pump inhibitors after antireflux surgery: a nationwide register-based follow-up study
por: Lødrup, Anders, et al.
Publicado: (2014)

The stem cell organisation, and the proliferative and gene expression profile of Barrett's epithelium, replicates pyloric-type gastric glands
por: Lavery, Danielle L, et al.
Publicado: (2014)

The human squamous oesophagus has widespread capacity for clonal expansion from cells at diverse stages of differentiation
por: Barbera, Mariagnese, et al.
Publicado: (2015)

Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry
por: Haidry, R J, et al.
Publicado: (2015)

Methylation panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic biopsies and non-endoscopic cytology specimens
por: Chettouh, Hamza, et al.
Publicado: (2018)

Developing patient-orientated Barrett’s oesophagus services: the role of dedicated services
por: Ratcliffe, Elizabeth, et al.
Publicado: (2022)

Wide-area transepithelial sampling in adjunct to forceps biopsy increases the absolute detection rates of Barrett’s oesophagus and oesophageal dysplasia: a meta-analysis and systematic review
por: Suresh Kumar, Vishnu Charan, et al.
Publicado: (2020)

Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study
por: Mizokami, Yuji, et al.
Publicado: (2018)

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review
por: Chinzon, Décio, et al.
Publicado: (2021)

Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
por: Cho, Yu Kyung, et al.
Publicado: (2022)

Incidence of metachronous visible lesions in patients referred for radiofrequency ablation (RFA) therapy for early Barrett's neoplasia: a single-centre experience
por: Ortiz-Fernández-Sordo, J, et al.
Publicado: (2016)

Monitoring the premalignant potential of Barrett's oesophagus'
por: Graham, David, et al.
Publicado: (2016)

Guide to managing persistent upper gastrointestinal symptoms during and after treatment for cancer
por: Andreyev, H Jervoise N, et al.
Publicado: (2017)

Mutational load may predict risk of progression in patients with Barrett’s oesophagus and indefinite for dysplasia: a pilot study
por: Trindade, Arvind J, et al.
Publicado: (2019)

Volumetric laser endomicroscopy features of dysplasia at the gastric cardia in Barrett’s oesophagus: results from an observational cohort study
por: Trindade, Arvind J, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p0p7lvumhe0q7qup5gujov0tm7